BCX Bioceltix S.A.

15.78USD63.40 PLN · GPW-4.08%Mkt Cap: 87.29M USDP/E: —

Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BC…

Key Statistics

Company
Market Cap87.29M USD
Enterprise Value73.18M USD
Revenue (TTM)—
Gross Profit-508.47K USD
Net Income (TTM)-3.77M USD
Revenue/Share—
Last Price15.78 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees49
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLBCLTX00019
Valuation
P/E (Trailing)—
P/E (Forward)-15.85
PEG—
EV/EBITDA-16.42
EV/Revenue—
P/S—
P/B5.61
EPS (TTM)-0.86 USD
EPS (Forward)—
52W Range
14.3114% of range24.64
52W High24.64 USD
52W Low14.31 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-20.69%
ROA-20.04%
ROIC-291.82%
ROCE-20.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.97M USD
CapEx (TTM)490.30K USD
FCF Margin—
FCF Yield-4.66%
Net Debt-14.10M USD
Net Debt/EBITDA3.16
Net Debt/FCF—
Balance Sheet
Debt/Equity0.00
Current Ratio19.30
Quick Ratio19.26
Book Value/Sh2.81 USD
Cash/Share2.56 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)29.61 USD
Upside (mean)+87.7%
Target Range29.61 USD – 29.61 USD
# Analysts1
Ownership
Shares Out.5.53M
Float4.44M
Insiders15.12%
Institutions28.83%
Technical
SMA 5017.66 (-10.7%)
SMA 20020.08 (-21.4%)
Beta0.93
S&P 52W Chg8.68%
Avg Vol (30d)10.24K
Avg Vol (10d)4.12K
Technical Indicators
RSI (14)39.5
MACD-1.2396
MACD Signal-0.9949
MACD Hist.-0.2447
BB Upper18.25 USD
BB Middle16.97 USD
BB Lower15.69 USD
BB Width15.05%
ATR (14)0.7623 USD
Vol Ratio (20d)0.66x

About Bioceltix (WSE: BCX)

›

Bioceltix (WSE: BCX) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 49 employees.

The shares were at 63.40 PLN on 20 November 2026, down 34.3% over 52 weeks. Its 52-week range is 57.50 PLN to 99.00 PLN: the price is 36.0% below the high and 10.3% above the low.

Its market capitalisation is 350.74M PLN.

Bioceltix reports return on equity of -20.7% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 56.66M PLN. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 119.00 PLN is 87.7% above the current price.